Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

scRNA+VDJ-seq in SLE: Insights into autoreactive T and B cell subsets, features, and therapeutic applications.

Created on 12 Aug 2026

Authors

Hailin Zou, Guangtian Tang, Xueqi Hao, Xinsheng Yao

Published in

Clinical immunology (Orlando, Fla.). Pages 110760. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

The adaptive autoimmune process in SLE is complex, and conventional techniques cannot resolve disease-associated T/B lymphocyte clones at a single-cell granularity. Single-cell RNA sequencing combined with single-cell V(D)J sequencing (scRNA+VDJ-seq) enables simultaneous profiling of cellular transcriptomes and TCR/BCR repertoires. This review highlights recent advances in scRNA+VDJ-seq in SLE and related autoimmune disorders, elucidating the link between receptor clonality, gene expression, and effector phenotypes. It delineates clonal expansion, biased V(D)J usage, and aberrant exhaustion in SLE, and compares T/B cell immune phenotypes across lupus nephritis, RA, pSS, and AS. The review also summarizes CD19 CAR-T and PD-1 agonist applications. Furthermore, it discusses AI integration with scRNA+VDJ-seq to analyze autoreactive T/B cells in SLE: from data integration to clinical translation, and assesses the clinical translational potential of this technology, offering novel targets and strategies for SLE diagnosis, personalized treatment, and prognosis.

PMID:
42580607
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement